LP
DRNA

LMR Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

LMR Partners’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,757
Closed -$35K – 528
2016
Q2 		$35K Buy
+11,757
New +$48.3K 0.01% 457

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LMR Partners's DRNA Position: Q3 2016 in Review

LMR Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2016, closing a stake of 11,757 shares — an estimated $35K sold.

LMR Partners first reported a position in DRNA in Q2 2016 and held it in 1 quarter. The position peaked at $35K in Q2 2016. 48 funds tracked by Wall St. Rank hold DRNA as of Q3 2016.

  • LMR Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • LMR Partners sold 11,757 Dicerna Pharmaceuticals, Inc. shares in Q3 2016, an estimated $35K.
  • LMR Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • LMR Partners's Dicerna Pharmaceuticals, Inc. position peaked at $35K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.